Marie Shamseddin

Marie Shamseddin

Auto-generated profile, based on publicly available information

Marie Shamseddin

Swiss Institute for Experimental Cancer Research School of Life Sciences Ecole Polytechnique Fédérale de Lausanne Lausanne Switzerland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
DADalya Ataca
Dalya Ataca
PAPatrick Aouad
Patrick Aouad
CCCéline Constantin
Céline Constantin
CLCsaba Laszlo
Csaba Laszlo
MBManfred Beleut
Manfred Beleut
CBCathrin Brisken
Cathrin Brisken
Estrogens and progesterone control breast development and carcinogenesis via their cognate receptors expressed in a subset of luminal cells in the mammary epithelium. How they control the extracellular matrix, important to breast physiology and tumorigenesis, remains unclear. Here we report that both hormones induce the secreted protease Adamts18 in myoepithelial cells by controlling Wnt4 expression with consequent paracrine canonical Wnt signaling activation. Adamts18 is required for stem cell activation, has multiple binding partners in the basement membrane and interacts genetically with the basal membrane-specific proteoglycan, Col18a1, pointing to the basement membrane as part of the stem cell niche. In vitro, ADAMTS18 cleaves fibronectin; in vivo, Adamts18 deletion causes increased collagen deposition during puberty, which results in impaired Hippo signaling and reduced Fgfr2 expression both of which control stem cell function. Thus, Adamts18 links luminal hormone receptor signaling to basement membrane remodeling and stem cell activation.

27 May 2021 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
MSMarie Shamseddin
Marie Shamseddin
FMFabio De Martino
Fabio De Martino
CCCéline Constantin
Céline Constantin
VSValentina Scabia
Valentina Scabia
ALAnne‐Sophie Lancelot
Anne‐Sophie Lancelot
CBCathrin Brisken
Cathrin Brisken
Hormonal contraception exposes women to synthetic progesterone receptor (PR) agonists, progestins, and transiently increases breast cancer risk. How progesterone and progestins affect the breast epithelium is poorly understood because we lack adequate models to study this. We hypothesized that individual progestins differentially affect breast epithelial cell proliferation and hence breast cancer risk. Using mouse mammary tissue ex vivo, we show that testosterone‐related progestins induce the PR target and mediator of PR signaling‐induced cell proliferation receptor activator of NF‐κB ligand (Rankl), whereas progestins with anti‐androgenic properties in reporter assays do not. We develop intraductal xenografts of human breast epithelial cells from 36 women, show they remain hormone‐responsive and that progesterone and the androgenic progestins, desogestrel, gestodene, and levonorgestrel, promote proliferation but the anti‐androgenic, chlormadinone, and cyproterone acetate, do not. Prolonged exposure to androgenic progestins elicits hyperproliferation with cytologic changes. Androgen receptor inhibition interferes with PR agonist‐ and levonorgestrel‐induced RANKL expression and reduces levonorgestrel‐driven cell proliferation. Thus, different progestins have distinct biological activities in the breast epithelium to be considered for more informed choices in hormonal contraception.

1 October 2019 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Open access
CLCsaba Ferenc Laszlo
Csaba Ferenc Laszlo
JMJonathan Paz Montoya
Jonathan Paz Montoya
MSMarie Shamseddin
Marie Shamseddin
FMFabio De Martino
Fabio De Martino
ABAlexandre Beguin
Alexandre Beguin
CBCathrin Brisken
Cathrin Brisken
In the context of hormonal contraception and hormone replacement therapy (HRT), many women are exposed to exogenous hormones. Current use of hormonal contraception with combined ethinyl estradiol and different progestins bestows a breast cancer relative risk (RR) of 1.2- while combined HRT has a RR of 2. Although these exposures present an important public health issue, little is known about the effects of individual progestins on the breast and other tissues. Increasing availability of large scale biobanks, high throughput analyses and data management tools enable ever expanding, sophisticated population studies. In order to address the impact of distinct progestins on various health indicators, it is desirable to accurately quantify progestins in clinical samples. Here we have developed and validated a high resolution liquid chromatography mass spectrometry (LC-MS) targeted method for the simultaneous quantification of 11 synthetic progestins widely used in oral contraceptives, gestodene, levonorgestrel, etonogestrel, chlormadinone acetate, cyproterone acetate, drospirenone, desacetyl norgestimate, medroxyprogesterone acetate, norethindrone, dienogest, nomegestrol acetate, and 4 endogenous steroid hormones, progesterone, testosterone, androstenedione, and cortisol in blood samples. This highly specific quantitative analysis with high resolution Orbitrap technology detects and quantifies 15 compounds using their internal standard counterparts in a single 12 min LC-MS run. Sensitivity is attained by the use of the instrument in targeted selected ion monitoring mode. Lower limit of quantitation ranges from 2.4 pg/ml for drospirenone to 78.1 pg/ml for chlormadinone acetate. The method provides comprehensive progestin panel measurements with as little as 50 μl of murine or human plasma.

1 July 2013 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
RCRoya Cheraghi
Roya Cheraghi
SHSaman Hosseinkhani
Saman Hosseinkhani
JDJamshid Davoodi
Jamshid Davoodi
MNMahboobeh Nazari
Mahboobeh Nazari
ZAZahra Amini-Bayat
Zahra Amini-Bayat
FGFatemeh Gheidari
Fatemeh Gheidari

8 January 2015 in Journal of Visualized Experiments
Verified
Journal Article
Open access
PDF file
GSGeorge SFLOMOS
George SFLOMOS
MSMarie Shamseddin
Marie Shamseddin
CBCathrin Brisken
Cathrin Brisken
We have developed a novel ex vivo model to study hormone action in the human breast. It is based on tissue microstructures...